Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients

Transplantation

Volumn 94, Issue 5, 2012, Pages 465-472

  Vafadari, Ramin ^a   Quaedackers, Monique E ^a   Kho, Marcia M ^a   Mol, Wendy M ^a   Chan, Gary ^b   Weimar, Willem ^a   Baan, Carla C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PFIZER INC   (United States)

Author keywords

Flow cytometry; Pharmacodynamic monitoring; STAT5; Tofacitinib

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STAT5 PROTEIN; TACROLIMUS; TOFACITINIB;

ACUTE GRAFT REJECTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IC 50; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; JANUS KINASES; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES; NETHERLANDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866337685     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182626b5a     Document Type: Article

References (22)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. van Gurp EA, Schoordijk-Verschoor W, Klepper M, et al. The effect of the JAK inhibitor CP-690, 550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009; 87: 79.
3. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitorY free immunosuppression based on the JAK inhibitor CP-690, 550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936.
4. Klupp J, Holt DW, van Gelder T. How pharmacokinetic and phar-macodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol 2002; 9: 211.
5. de Jonge H, Naesens M, Kuypers DR. New insights into the pharma-cokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416.
6. Feng Y, Mitchison TJ, Bender A, et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov 2009; 8: 567.
7. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690, 550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010; 53: 8468.
8. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by F(c) family cytokines. Nat Rev Immunol 2009; 9: 480.
9. Johnston JA, Bacon CM, Riedy MC, et al. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol 1996; 60: 441.
10. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ al-lograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875.
11. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
12. Vincenti F, Silva H, Busque S, et al. Efficacy and safety of CP-690, 550-MPA combination regimens in de novo kidney transplant patients: 12-month final results of a phase 2b study. Am J Transplant 2011; 11(suppl 2): 30.
13. Vincenti F, Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib in de novo kidney transplant patients: efficacy, renal function, and safety at 1 year. Am J Transplant 2012 [June 12, 2012; published online ahead of print DOI: 10.1111/j.1600-6143.2012.04127.x].
14. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
15. Vafadari R, Weimar W, Baan CC. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: Analysis of the JAK-STAT signaling pathway. Clin Chim Acta 2012; 413: 1398.
16. Schluns KS, Kieper WC, Jameson SC, et al. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1: 426.
17. Blanchet B, Hulin A, Duvoux C, et al. Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC. Anal Biochem 2003; 312: 1.
18. Sester U, Wilkens H, van Bentum K, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J 2009; 34: 702.
19. Caruso R, Perico N, Cattaneo D, et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem 2001; 47: 1679.
20. Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhibitor CP-690, 550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant 2010; 10: 1785.
21. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003; 55: 61.
22. Quaedackers ME, Mol W, Korevaar SS, et al. Monitoring of the im-munomodulatory effect of CP-690, 550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation 2009; 88: 1002.